ArticleScientific reports2025
AP-1 elements in the promoter and second intron mediate endoplasmic reticulum stress-induced expression of the GPAT3 gene.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An excessive accumulation of hepatic lipids is a characteristic feature of metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe form, metabolic dysfunction-associated steatohepatitis (MASH). Acyl-CoA:glycerol-sn-3-phosphate acyltransferase 3 (GPAT3) and other members of the GPAT family are enzymes which play an important role in glycerolipid synthesis. Previous articles have reported that GPAT3 mRNA and ER stress marker genes are upregulated in patients with MASH. Here, we study the regulatory mechanism of GPAT3 gene expression in human hepatoma cells suffering from ER stress. Transcriptome profiling showed that among the genes implicated in the formation of glycerolipids, GPAT3 is one of the most strongly activated genes in response to tunicamycin, an inducer of ER stress. CRISPR/Cas9-mediated disruption of activating transcription factor 4 (ATF4) resulted in reduced GPAT3 expression under ER stress. Luciferase reporter assays of GPAT3 gene fragments encompassing ATF4 ChIP-seq peaks and mutational analysis revealed that activator protein-1 (AP-1) sites located in GPAT3 promoter and intron 2 mediate the activation of transcription in response to ER stress and ATF4. CRISPR/Cas9-mediated deletion of the region containing AP-1 sites from GPAT3 intron 2 caused a reduction of GPAT3 expression and triglyceride content in both unstressed cells and under ER stress. Thus, the results indicate that the induction of GPAT3 expression in response to ER stress is mediated by ATF4 via AP-1 elements in the promoter and second intron.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.